| abstract |
The present invention relates to combinations comprising a proteasome inhibitor and a cyclic peptide comprising an exposed Arg-Gly-asp (rgd) moiety. In particular, the present invention relates to proteasome inhibitors comprising an inhibitor selected from the group consisting of boronic ester, epoxy ketone, peptide aldehyde and β -lactone protease inhibitors; and a cyclic peptide containing an exposed Arg-Gly-Asp (RGD) moiety. More specifically, the present invention relates to a proteasome inhibitor comprising a compound selected from the group consisting of bortezomib, delazolamide, esxazomib, carfilzomib, oprozomib, MG132, and marizomib; and a cyclic peptide containing an exposed Arg-Gly-Asp (RGD) moiety. |